IOVA - Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting | Benzinga
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, will be highlighted at the upcoming 2024 ASCO Annual Meeting to be held May 31- June 4, 2024, at McCormick Place in Chicago, IL and online.
ASCO 2024 Highlights for Iovance
- Oral Presentation: Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A (Abstract 9505)
- Session: Melanoma/Skin Cancers, Friday, May 31, 2024, 2:45 – 5:45pm ET
- Poster: IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens (Abstract 2552)
- Session: Developmental Therapeutic – Immunotherapy, Saturday, June 1, 2024, 9:00 am – 12:00 pm ET
- Poster: Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients (Abstract 9594)
- Session: Melanoma/Skin Cancers, Saturday, June 1, 2024, 1:30 – 4:30 pm ET
Iovance will host an event on the evening of Friday, May 31, 2024 to summarize the data highlights at ASCO. The live and archived event webcast will be available in the Investors section of the company's website at www.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other ...